HC Wainwright Predicts Higher Earnings for Coya Therapeutics

Coya Therapeutics, Inc. (NASDAQ:COYA) – Equities researchers at HC Wainwright lifted their Q1 2026 earnings estimates for Coya Therapeutics in a note issued to investors on Monday, February 2nd. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.33) per share for the quarter, up from their previous estimate of ($0.37). HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Coya Therapeutics’ current full-year earnings is ($1.15) per share. HC Wainwright also issued estimates for Coya Therapeutics’ Q2 2026 earnings at ($0.33) EPS, Q3 2026 earnings at ($0.40) EPS, Q4 2026 earnings at ($0.46) EPS and FY2026 earnings at ($1.52) EPS.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.12). Coya Therapeutics had a negative return on equity of 55.76% and a negative net margin of 462.24%.The firm had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $3.70 million.

Several other equities research analysts also recently weighed in on the company. D. Boral Capital reiterated a “buy” rating and issued a $15.00 price target on shares of Coya Therapeutics in a report on Wednesday, January 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Wednesday, January 21st. Chardan Capital reiterated a “buy” rating and issued a $14.00 target price on shares of Coya Therapeutics in a research note on Thursday, January 8th. Lake Street Capital reissued a “buy” rating and set a $17.00 target price on shares of Coya Therapeutics in a research note on Wednesday, November 5th. Finally, BTIG Research upped their price target on shares of Coya Therapeutics from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Coya Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $16.00.

Coya Therapeutics Price Performance

Shares of NASDAQ COYA opened at $4.76 on Wednesday. Coya Therapeutics has a 1 year low of $3.94 and a 1 year high of $8.29. The firm has a 50-day simple moving average of $5.33 and a two-hundred day simple moving average of $5.87. The company has a market cap of $99.58 million, a P/E ratio of -4.29 and a beta of 0.27.

Hedge Funds Weigh In On Coya Therapeutics

Several institutional investors have recently bought and sold shares of COYA. CM Management LLC raised its stake in Coya Therapeutics by 16.7% in the fourth quarter. CM Management LLC now owns 350,000 shares of the company’s stock worth $2,030,000 after buying an additional 50,000 shares in the last quarter. Dauntless Investment Group LLC increased its holdings in shares of Coya Therapeutics by 199.5% in the 3rd quarter. Dauntless Investment Group LLC now owns 153,021 shares of the company’s stock valued at $872,000 after acquiring an additional 101,932 shares during the period. Citadel Advisors LLC raised its position in shares of Coya Therapeutics by 51.3% in the 3rd quarter. Citadel Advisors LLC now owns 65,240 shares of the company’s stock worth $372,000 after acquiring an additional 22,120 shares in the last quarter. Jane Street Group LLC raised its position in shares of Coya Therapeutics by 101.7% in the 1st quarter. Jane Street Group LLC now owns 26,137 shares of the company’s stock worth $169,000 after acquiring an additional 13,176 shares in the last quarter. Finally, Prosperity Wealth Management Inc. lifted its stake in shares of Coya Therapeutics by 16.4% during the 3rd quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company’s stock worth $136,000 after purchasing an additional 3,350 shares during the last quarter. 39.75% of the stock is owned by hedge funds and other institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.